AVLN

Avalyn Pharma Inc

25.88

Nov 02 • 2:44 PM ET +0.25 (0.98%)

Healthcare Biotechnology USA Small NASD

Peers: CTNM MNKD SVRA INSM PLRX LQDA TECX UTHR IVA UPB

| Held by: VTI IWM VXF XPH IWO VTWO SCHA TMSL IHE IWN

Index	RUT
Market Cap	1.15B
Enterprise Value	812.02M
Income	-
Sales	-
Book/sh	8.99
Cash/sh	7.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	50
IPO	Apr 30, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.88
P/C	3.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	33.10
Current Ratio	33.10
Debt/Eq	0.04
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.96
EPS next Q	-0.71
EPS this Y	13.10%
EPS next Y	9.65%
EPS next 5Y	7.23%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-26.17% -

Insider Own	39.92%
Insider Trans	3.24%
Inst Own	66.18%
Inst Trans	153.85%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.44%
SMA50	-13.46%
SMA200	-13.62%
Trades

Shs Outstand	44.33M
Shs Float	26.64M
Short Float	8.84%
Short Ratio	8.35
Short Interest	2.35M
52W High	40.17 -35.57%
52W Low	22.24 16.37%
Volatility	7.34% 7.14%
ATR (14)	1.84
RSI (14)	45.53
Beta	-
Rel Volume	1.10
Avg Volume	282.05K
Volume	253,237

Perf Week	-4.64%
Perf Month	-8.00%
Perf Quarter	-15.78%
Perf Half Y	-10.97%
Perf YTD	-0.46%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.20
Target Price	61.80
Prev Close	25.63
Price	25.88
Change %	0.98%

Consensus

Strong Buy

Avg. Price Target

$61.80

Implied Upside

+138.8%

Analysts5incl. previous ratings

Rating Distribution5 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 02, 2026	Initiated	RRaymond James	Outperform	$60	+131.8%
May 26, 2026	Initiated	MMorgan Stanley	Overweight	$53	+104.8%
May 26, 2026	Initiated	JJefferies	Buy	$52	+100.9%
May 26, 2026	Initiated	GGuggenheim	Buy	$80	+209.1%
May 26, 2026	Initiated	EEvercore ISI	Outperform	$51	+97.1%

Sep-21-26 09:00AM	Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile (GlobeNewswire)
Sep-16-26 04:01PM	Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors (GlobeNewswire)
Sep-08-26 08:00AM	Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
08:00AM	Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis (GlobeNewswire)
Aug-24-26 04:01PM	Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 (GlobeNewswire)
08:28AM	Loading…
Aug-12-26 08:28AM	Avalyn: Q2 Earnings Snapshot (Associated Press) +5.41%
08:00AM	Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jun-17-26 08:00AM	Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis (GlobeNewswire)
Jun-03-26 08:07AM	Avalyn: Q1 Earnings Snapshot (Associated Press)
07:00AM	Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-27-26 08:00AM	Avalyn to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-26 08:00AM	Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 (GlobeNewswire)
May-05-26 04:01PM	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference (GlobeNewswire) -5.64%
May-01-26 04:01PM	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

CEOMs. Lyn Baranowski

CFO & Chief Business OfficerMr. Douglas R. Carlson

Ph.D.Dr. Melissa Rhodes DABT

Chief Medical OfficerDr. Howard M. Lazarus M.D.

Senior Director of IR & Corporate CommunicationsMs. Cassie Saitow

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVLN

Avalyn Pharma Inc

Upgrade your Finviz experience